Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,638.70down ₹49.10 (1.33%)BSE ₹3,637.90
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,687.80.
2 Nov: open ₹3,687.80, high ₹3,718.20, low ₹3,613.60
52-week range of traded prices to 2 Nov 2026
₹3,589.00Low, 23 Oct 2026₹5,339.00High, 13 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,646 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.96
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,74259.3% delivered
Pfizer share news and announcements
659 announcements, routine notices left out, newest first. Page 11 of 14.
Apr 2014
25 Apr · Meeting
22 Apr · Board meeting
Inter alia, to consider and take on record the Audited Financial Results for the quarter January 1, 2014 to March 31, 2014 and for the year ended March 31, 2014. At the said meeting, the Board of Directors will also consider recommendation of final Dividend, if any, for the year ended March 31, 2014. The Trading Window for trading in the Equity shares of the Company is closed from April 23, 2014 to May 2, 2014, both days inclusive.
Mar 2014
21 Mar · Court Convened Meeting Updates
Feb 2014
25 Feb · News Verification
News Verification : The media had reports that "Pfizer Stock Gains Over 20% on Stake Recast Plans". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Pfizer Limited has vide its letter inter-alia stated,"The news article is speculative and was not authorized by, or attributable to any statements made by or on behalf of, Pfizer Limited. For instance, the article mentions unsubstantiated market rumours of a possible delisting of Pfizer Limited. Pfizer Limited is not aware of any discussions or proposals by its promoters to delist the company's shares from Indian markets. As regards the transfer of shares of Pfizer Limited, such transaction is being undertaken directly between shareholders of Pfizer Limited and to which, Pfizer Limited was not a transacting party. Pfizer Limited understands that fillings have been made by the acquiring entity i.e. Pfizer East India B.V., Netherlands, under applicable provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. We understand that such transfers are being undertaken as part of the global internal corporate restructuring plan of the Pfizer Group, as reported by us previously. We do not believe that the present transfers have bearing on the stock price of Pfizer Limited, given especially that ultimate control of Pfizer Limited remains unchanged."
Jan 2014
31 Jan · Results
22 Jan · Updates
Trading Window for trading in the Equity Shares of the Company is closed from January 22, 2014 to January 31, 2014 both days inclusive.21 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2013.
Dec 2013
Nov 2013
25 Nov · Corporate action
Company has fixed Record Date as December 6, 2013 for the purpose of Interim dividend25 Nov · Dividend
Board of Directors of the Company at its meeting held on November 23, 2013 has approved the payment of Interim Dividend of Rs 360/- per equity share of Rs.10/- each (3600%) to the shareholders of the Company.25 Nov · Dividend
Interim Dividend will be paid on December 17, 2013.20 Nov · Board meeting
Inter alia, to transact the following:(1) To consider a Scheme of Amalgamation of Wyeth Limited with the Company.(2) To consider declaration of Interim Dividend.11 Nov · Results
Oct 2013
23 Oct · Meeting
Sep 2013
Jul 2013
29 Jul · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from August 30, 2013 to September 6, 2013 (both days inclusive) for the purpose of determining the eligibility of payment of dividend. Further, the Annual General Meeting of the Company is scheduled to be held on September 06, 2013.29 Jul · Dividend
Dividend recommended in the Board Meeting held on May 14, 2013 if declared at the Annual General Meeting, shall be paid on September 12, 2013.16 Jul · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
15 May · Management
Board of Directors of the Company at its meeting held on May 14, 2013, has appointed Mr S Sridhar as an Additional Director on the Board of the Company with effect from May 14, 2013.The appointment and remuneration of Mr S Sridhar, Whole-time Director will be subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.14 May · Dividend
Board of Directors at its meeting held on May 14, 2013 has recommended a normal dividend of Rs.12.50/- per Equity share of Rs.10 each (125%) and special Dividend of Rs. 20/- equity share of Rs. 10/- each (200%) on account of sale of animal health business aggregating to a total Dividend of Rs. 32.50/- per Equity share of Rs. 10/- each (325%) for the year ended March 31, 2013. The Said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on September 12, 2013.14 May · Results
8 May · Board meeting
Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 03, 2013 To consider and take on record the Audited Financial Results for the quarter, January 1, 2013 to March 31, 2013 and the year ended March 31, 2013 and to consider recommendation of Dividend, if any, for the year ended March 31, 2013 and also informed dated May 03, 2013 about the postponement of the said Board Meeting. The Company has now informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 14, 2013, inter alia, to consider and take on record the Audited Financial Results for the quarter, January 01, 2013 to March 31, 2013 and the year ended March 31, 2013. At the said meeting, the Board of Directors will also consider recommendation of Dividend, if any, for the year ended March 31, 2013.Not held on this date
3 May · Board Meeting Postponed
Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 03, 2013 To consider and take on record the Audited Financial Results for the quarter, January 1, 2013 to March 31, 2013 and the year ended March 31, 2013 and to consider recommendation of Dividend, if any, for the year ended March 31, 2013.The Company has now informed the Exchange that that due to delay in finalization of accounts and completion of audit, the said Board Meeting has been postponed and the new date of the Board Meeting to consider and take on record the Audited Financial Results for the year and quarter ended March 31, 2013 and to recommend dividend, if any, thereon will be intimated separately.
Apr 2013
Feb 2013
8 Feb · Retirement
Mr Sunil Madhok, Executive Director, Business Operations has retired from the services of the Company with effect from January 31, 2013 and has also resigned from the Board effective the said date.The Board of Directors of the Company at its meeting held on February 07, 2013 has accepted the resignation of Mr Sunil Madhok with effect from close of business on January 31, 2013.
Jan 2013
29 Jan · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2012.
Dec 2012
Nov 2012
8 Nov · Board meeting
Board of Directors of the Company at its meeting held on November 08, 2012 has approved, subject to receipt of prior regulatory approvals, the sale of its wholly owned subsidiary Pfizer Animal Pharma Private Limited to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of Rs. 471.60 Crores (Rupees Four Hundred and Seventy One Crores and Sixty Lakhs only).
Oct 2012
26 Oct · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2012.
Sep 2012
Aug 2012
6 Aug · Disclosure of Voting Pattern - Clause 35A